Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.
about
Systemic treatments for metastatic cutaneous melanomaInterferon alpha for the adjuvant treatment of cutaneous melanomaInterferon alpha for the adjuvant treatment of cutaneous melanomaInterleukin-15 biology and its therapeutic implications in cancerChinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)Insight to drug delivery aspects for colorectal cancerLong-term survival as a treatment benchmark in melanoma: latest results and clinical implicationsPredictive factors for immunotherapy in melanomaThe past, present and future of immunotherapy against tumorHarnessing immunosurveillance: current developments and future directions in cancer immunotherapyUpdate on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape.Imaging Biomarkers in ImmunotherapySonography of the primary cutaneous melanoma: a reviewTranscriptional dissection of melanoma identifies a high-risk subtype underlying TP53 family genes and epigenome deregulationTargeted Therapy Database (TTD): a model to match patient's molecular profile with current knowledge on cancer biologyState of melanoma: an historic overview of a field in transition.Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases.Systemic Immune-Inflammation Index and Circulating T-Cell Immune Index Predict Outcomes in High-Risk Acral Melanoma Patients Treated with High-Dose InterferonUbiquitination-dependent regulation of signaling receptors in cancer.Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia GroupIL28B polymorphism cannot predict response to interferon alpha treatment in patients with melanoma.A new understanding in the epidemiology of melanomaCutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Dabrafenib and its potential for the treatment of metastatic melanoma.STAT3 Single Nucleotide Polymorphism rs4796793 SNP Does Not Correlate with Response to Adjuvant IFNα Therapy in Stage III Melanoma Patients.Adjuvant Immunotherapy and Radiation in the Management of High-risk Resected Melanoma.Evaluating biomarkers in melanoma.Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patientsRoles of the immune system in skin cancer.Trends in the treatment and survival for local and regional cutaneous melanoma in a US population-based study.Gene Expression Profiling and Pathway Network Analysis Predicts a Novel Antitumor Function for a Botanical-Derived Drug, PG2IFN-α in the treatment of melanomaSystematic review of medical treatment in melanoma: current status and future prospects.Racial differences in survival after surgical treatment for melanomaAdjuvant therapy: melanomaPrimary malignant melanoma of the stomach: report of a case.15th international congress of Parkinson's disease and movement disorders and inaugural melanoma and cutaneous malignancy meetingRetinopathy associated with adjuvant high-dose interferon-α2b in a patient with resected melanoma: a case report and review of the literature.Interferon Alpha Signalling and Its Relevance for the Upregulatory Effect of Transporter Proteins Associated with Antigen Processing (TAP) in Patients with Malignant Melanoma.Controversies in the evaluation and management of atypical melanocytic proliferations in children, adolescents, and young adults.
P2860
Q24194804-6E6F952B-631A-4C01-B64A-05937A4B06ECQ24201908-3A0B4335-5EC1-4EA5-92B7-21F5F11558A7Q24235257-93F436AA-952F-4109-BA4F-9F44BDB58012Q24595605-3F5A0012-21B4-4DC8-8E24-3981D464C4F9Q26770492-348587CC-AA04-41E1-BC7D-78E13975A97EQ26774682-3E8EDA79-7A61-4CFF-BFB8-0129E4B64268Q26775546-DD792968-74C6-4C70-84D4-7E0CBF7CE9C7Q26778765-99DA7B58-FE37-453D-AC12-065CDE34DA45Q26799896-86C98890-41F3-4828-BD63-D9ADB295EC3FQ27021570-7BD6EE28-8972-4DC3-A815-A40AED7B0E68Q27691824-D8A618AC-5D2C-4AA4-9D91-4525A16751D0Q28079871-7A0A1D1C-456E-4A47-8B80-1232B446ABDFQ30468180-F997A7DF-0651-4D2D-860E-D33C15BC2D1EQ33631126-36CC60CB-6CE8-4C42-8151-7C6F6C077F71Q33656600-D99A1795-E3C5-4BA6-9384-6999C9192E62Q33693906-B569B327-6E21-4AD2-B648-ED67B2C741BEQ33829284-0C2D65DD-AABC-423D-9934-8AC5FF882E33Q33904496-213E737C-03D1-425E-BD7C-92A6CA976593Q34365210-5533E24A-8309-4E9A-AC8E-4D309DC19176Q34484199-A58C2C60-5894-4170-919D-4ED64E3B2AB2Q34497983-80A59EBC-6A12-499C-9087-9461D49DF68EQ34625205-B23D5EDC-150D-41A9-AC5E-484C1793CC42Q34642874-ABE3F733-652B-4A48-AAC3-7024FD894BFBQ34646614-16FC2C3D-281F-4CF7-B170-871F03FE09BEQ34931400-F9D1D11D-30B5-4CDA-9499-37F37F2728B8Q34986199-2DAB88B1-9A64-4C36-9525-28C007A720ABQ35005677-54348703-7E4D-40E9-8C15-812A0A2D6F79Q35044537-104F3398-85E8-4EEA-84E4-ACDF23AC32FCQ35403714-F112BCE7-647E-45BF-9AD8-223167E25F36Q35528902-74A0298A-31EA-48F7-B94D-66D3558B55B6Q35564075-C5029340-8EDA-4872-81DD-385B0C3790B8Q35572008-864BA7A6-8646-4447-A732-5FE9EBC4CB34Q35584299-46243620-CF20-4BF6-800F-D432E75211BFQ35600763-E3335445-C095-4849-8D53-76B2B45841B7Q35636225-E0E32E49-45CA-453F-AB7D-D39530215186Q35691064-3188F2F3-CDFD-4903-A584-FAA18385251AQ35752818-CCDB08DE-C541-4857-A499-31C01C648CA6Q35863891-71BE54BE-0645-4BD7-AA64-958626DF0290Q35886748-D66E39DD-41A5-434B-9059-CBD4E157589BQ35933519-BC55F361-53A4-41EC-AED5-241DAD4B6756
P2860
Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 February 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Interferon alpha adjuvant ther ...... atic review and meta-analysis.
@en
Interferon alpha adjuvant ther ...... atic review and meta-analysis.
@nl
type
label
Interferon alpha adjuvant ther ...... atic review and meta-analysis.
@en
Interferon alpha adjuvant ther ...... atic review and meta-analysis.
@nl
prefLabel
Interferon alpha adjuvant ther ...... atic review and meta-analysis.
@en
Interferon alpha adjuvant ther ...... atic review and meta-analysis.
@nl
P356
P1476
Interferon alpha adjuvant ther ...... matic review and meta-analysis
@en
P2093
Donato Nitti
Simone Mocellin
P304
P356
10.1093/JNCI/DJQ009
P407
P577
2010-02-23T00:00:00Z